Jazz Pharmaceuticals

Jazz Pharmaceuticals(JAZZ)

CA - Palo Alto
Pharmaceutical10 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules

Jazz Pharmaceuticals is a life sciences company focused on Small Molecules.

Neurology
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (9)

2 discontinued products not shown

DEFITELIO
defibrotide sodium
Peak
INTRAVENOUS · SOLUTION
elucidated. In vitro , defibrotide sodium enhances the enzymatic activity of plasmin to hydrolyze fibrin clots. Studies evaluating the pharmacological effects of defibrotide sodium on endothelial cells (ECs) were conducted primarily in the human microvascular endothelial cell line. In vitro , defibrotide sodium increased tissue plasminogen activator (t-PA) and thrombomodulin expression, and decreased von Willebrand factor (vWF) and plasminogen activator inhibitor‑1 (PAI-1) expression, thereby reducing EC activation and increasing EC‑mediated fibrinolysis. Defibrotide sodium protected ECs from damage caused by chemotherapy, tumor necrosis factor-α (TNF-α), serum starvation, and perfusion.
knownrenalpulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT)
2016
0
EPIDIOLEX
cannabidiol
Peak
ORAL · SOLUTION
Cytochrome P450 2C8 Inhibitors
seizures associated with Lennox-Gastaut syndromeDravet syndrometuberous sclerosis complex in patients 1 year of age+1 more
2018
0
LUVOX
fluvoxamine maleate
LOE Approaching
ORAL · TABLET
2008
30
RYLAZE
asparaginase erwinia chrysanthemi (recombinant)-rywn
Peak
INTRAMUSCULAR · INJECTABLE
(recombinant)-rywn is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of RYLAZE is based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of asparagine synthetase have a reduced ability to synthesize asparagine, and therefore depend on an exogenous source of asparagine for survival.
2021
30
VYXEOS
(daunorubicin and cytarabine) liposome
Peak
INTRAVENOUS · POWDER
Nucleic Acid Synthesis Inhibitors
2017
0
XYREM
sodium oxybate
Peak
ORAL · SOLUTION
depressant. The mechanism of action of Sodium Oxybate Oral Solution in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of Sodium Oxybate Oral Solution on cataplexy and excessive daytime sleepiness are mediated through GABA B actions at noradrenergic and dopaminergic neurons, as well as at thalamocortical neurons.
cataplexyexcessive daytime sleepiness (EDS) in patients 7 years of ageolder with narcolepsy ()
2002
0
XYWAV
calcium, magnesium, potassium, and sodium oxybates
Peak
ORAL · SOLUTION
2020
0
ZEPZELCA
lurbinectedin
Peak
INTRAVENOUS · POWDER
Alkylating Activity
2020
0
ZIIHERA
zanidatamab-hrii
Growth
BsAbINJECTION · INJECTABLE
HER2-directed Antibody Interactions
2024
30

Pipeline & Clinical Trials

N/A
Clinical Trials (1)
NCT01888120Patient Registry of Intrathecal Ziconotide Management(PRIZM)
N/A
Sleep study
Hypersomnia
N/A
Clinical Trials (1)
NCT05850676Disentangling the Role of Depression in Hypersomnia
N/A
Epidiolex 100 mg/mL Oral Solution
Lennox Gastaut Syndrome
N/A
Clinical Trials (1)
NCT05485831Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
N/A
N/A
Clinical Trials (1)
NCT02073474An Observational Post-Marketing Safety Registry of Sativex®
N/A
ONC201
Glioma
N/A
Clinical Trials (1)
NCT05392374Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
N/A
N/A
Clinical Trials (1)
NCT04291937A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
N/A
Delphi Consensus Excessive Daytime Sleepiness in OSA
Obstructive Sleep Apnea
N/A
Clinical Trials (1)
NCT05055271Delphi Consensus Excessive Daytime Sleepiness in OSA
N/A
N/A
Clinical Trials (1)
NCT04578444An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer
N/A
Cannabidiol
Epilepsy
N/A
Clinical Trials (1)
NCT02660255Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy
N/A
Transition from Xyrem to Xywav
Narcolepsy
N/A
Clinical Trials (1)
NCT04803786A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
N/A
Asparaginase Erwinia Chrysanthemi
Acute Lymphoblastic Leukemia
N/A
Clinical Trials (1)
NCT04943952JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
N/A
Language of Sleepiness
Sleep
N/A
Clinical Trials (1)
NCT04323254Language of Sleepiness
N/A
N/A
Clinical Trials (1)
NCT06113237Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
N/A
Child and Adolescent Registry for Participants With Narcolepsy
Narcolepsy
N/A
Clinical Trials (1)
NCT04899947Child and Adolescent Registry for Participants With Narcolepsy
N/A
A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
Narcolepsy
N/A
Clinical Trials (1)
NCT02769780A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
N/A
N/A
Clinical Trials (1)
NCT03865589Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
N/A
Brincidofovir
Adenovirus
N/A
Clinical Trials (1)
NCT02420080A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304
N/A
N/A
Clinical Trials (1)
NCT02533115EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
N/A
Erwinia L-asparaginase
Leukemia, Acute Lymphoblastic
N/A
Clinical Trials (1)
NCT00590915Erwinase Master Treatment Protocol
N/A
Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopo
Adenovirus Infections, Human
N/A
Clinical Trials (1)
NCT04285788Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients
N/A
There are no interventions in this study. All participants complete online surveys.
Lung Cancer Patients
N/A
Epidiolex
Seizures
N/A
Clinical Trials (1)
NCT05772429Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
N/A
N/A
Clinical Trials (1)
NCT03526926A Post-Marketing Observational Study of VYXEOS™
N/A
N/A
Clinical Trials (1)
NCT04176042Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea
N/A
CMX001
Outcomes
N/A
Clinical Trials (1)
NCT02167685The Chimerix CMX001 Registry
N/A
N/A
Clinical Trials (1)
NCT04894591To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
N/A
N/A
Clinical Trials (1)
NCT05169307CPX-351 Real-World Effectiveness and Safety Study
N/A
N/A
Clinical Trials (1)
NCT06143839VYxeoS Liposomal Italian Observational Study iN the Real Practice
N/A
European VOD Registry
Hepatic Veno-Occlusive Disease
N/A
Clinical Trials (1)
NCT03032016European VOD Registry
N/A
ONC201
Glioma
N/A
Clinical Trials (1)
NCT04617002Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
N/A
Brincidofovir
Adenovirus
N/A
Clinical Trials (1)
NCT02596997Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
N/A
ONC201
Glioma
N/A
Clinical Trials (1)
NCT03134131Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
N/A
Phase 1
Clinical Trials (1)
NCT07377539A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
Phase 1
mPEG-r-crisantaspase
Hematologic Malignancies
Phase 1
Clinical Trials (1)
NCT01551524Phase I Study of mPEG-R-Crisantaspase Given IV
Phase 1
Phase 1
Clinical Trials (1)
NCT06961266A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
Phase 1
ODSH at 0.125 mg/kg/h
Protein Losing Enteropathy
Phase 1
Clinical Trials (1)
NCT01161641Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
Phase 1
Phase 1
Clinical Trials (1)
NCT03393611CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome
Phase 1
Phase 1
Clinical Trials (1)
NCT05558124CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
Phase 1
Erwinia Chrysanthemi asparaginase
Acute Lymphoblastic Leukemia (ALL)
Phase 1
Clinical Trials (1)
NCT02647190Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older
Phase 1
Epidiolex 100 mg/mL Oral Solution
Electrical Status Epilepticus of Slow-Wave Sleep
Phase 1
Clinical Trials (1)
NCT04721691Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).
Phase 1
Phase 1
Clinical Trials (1)
NCT01943682Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Phase 1
Phase 1
Clinical Trials (1)
NCT03416530ONC201 in Pediatric H3 K27M Gliomas
Phase 1
Phase 1
Clinical Trials (1)
NCT05651152A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants
Phase 1
Phase 1
Clinical Trials (1)
NCT01323569Abuse Potential of Sativex
Phase 1
CMX157
Healthy
Phase 1
Clinical Trials (1)
NCT01080820A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers
Phase 1
Phase 1
Clinical Trials (1)
NCT05244239Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT04075747A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia
Phase 1
Phase 1
Clinical Trials (1)
NCT04732065ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1
Paclitaxel
Ovarian Cancer
Phase 1
Clinical Trials (1)
NCT05636111Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
Phase 1
Phase 1
Clinical Trials (1)
NCT00875693A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 11 approved products, 149 clinical trials
Top TAs: Oncology, Neurology, Rare Diseases
H-1B (2023): 10 approvals
SEC Filings: 2 available
Portfolio Health
Growth1 (9%)
Peak7 (64%)
LOE Approaching3 (27%)
11 total products
Therapeutic Area Focus
Oncology
4 marketed104 pipeline
Neurology
54 pipeline
Rare Diseases
9 pipeline
Respiratory
1 marketed3 pipeline
Nephrology
1 marketed1 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$3.8B5%
R&D Spend
$850M(22%)44%
Net Income
$415M
Cash
$2.4B
Source: SEC 10-K Filing

Hiring Trend

Stable
0
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
10
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub